Although this hypothesis remains to be confirmed and we did not screen archived tumor biopsies for further mutations (except of one case with NGS testing, which showed no co‐occurring mutations), the trial findings are in line with published preclinical and clinical findings that inhibition of RAS/RAF/AKT signaling only might be insufficient in treatment of KRAS mutated patients.19, 20. This evidence concerns the gene AKT1 and neoplasm.